Compare BioNano Genomics Inc (BNGO) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Vistra Corp — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Vistra Corp trades at $159.33 (market cap $53.42B). The key difference: Vistra Corp is far larger — about 4047× BioNano Genomics Inc's market cap, and Vistra Corp pays a 0.58% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | VST | |
|---|---|---|
Market Cap | $13.20M | $53.42B |
Sector | Health | Technology |
52-Week High | $4.92 | $217.92 |
52-Week Low | $1.09 | $134.71 |
Enterprise Value | $15.81M | $75.17B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Vistra Corp. (VST) trades at $158.12, down 0.47% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings beating estimates, with revenue growth from $17.74B in 2025 to $19.4B projected for 2026. Net income margin improved to 11.52%, supported by robust cash flow from operations of $4.07B. Recent news highlights Vistra's positioning in the AI power demand surge and long-term power purchase agreements with major tech firms.
Outlook remains positive with a consensus price target of $230.50, implying significant upside. Key opportunities include exposure to growing electricity demand and strategic renewables focus. Risks involve power-price volatility, high debt levels, and execution of growth projects. Analyst sentiment is strongly bullish with 91% buy ratings, though investors should monitor Q2 2026 earnings due August 7 for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
